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Induction of synthetic lethality in mutant KRAS cells for non-small 
cell lung cancers chemoprevention and therapy 
Publication No. _____________ 
By Shaoyi Huang 
Advisor: Xiangwei Wu, Ph.D.   
Lung cancer is the leading cause of cancer death in both men and women in the United States and 
worldwide. Despite improvement in treatment strategies, the 5-year survival rate of lung cancer 
patients remains low. Thus, effective chemoprevention and treatment approaches are sorely 
needed. Mutations and activation of KRAS occur frequently in tobacco users and the early stage of 
development of non-small cell lung cancers (NSCLC). So they are thought to be the primary driver 
for lung carcinogenesis. My work showed that KRAS mutations and activations modulated the 
expression of TNF-related apoptosis-inducing ligand (TRAIL) receptors by up-regulating death 
receptors and down-regulating decoy receptors. In addition, we showed that KRAS suppresses 
cellular FADD-like IL-1β-converting enzyme (FLICE)-like inhibitory protein (c-FLIP) expression 
through activation of ERK/MAPK-mediated activation of c-MYC which means the mutant KRAS cells 
could be specifically targeted via TRAIL induced apoptosis. The expression level of Inhibitors of 
Apoptosis Proteins (IAPs) in mutant KRAS cells is usually high which could be overcome by the 
second mitochondria-derived activator of caspases (Smac) mimetic. So the combination of TRAIL 
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and Smac mimetic induced the synthetic lethal reaction specifically in the mutant-KRAS cells but 
not in normal lung cells and wild-type KRAS lung cancer cells. Therefore, a synthetic lethal 
interaction among TRAIL, Smac mimetic and KRAS mutations could be used as an approach for 
chemoprevention and treatment of NSCLC with KRAS mutations. Further data in animal 
experiments showed that short-term, intermittent treatment with TRAIL and Smac mimetic induced 
apoptosis in mutant KRAS cells and reduced tumor burden in a KRAS-induced pre-malignancy 
model and mutant KRAS NSCLC xenograft models. These results show the great potential benefit of 
a selective therapeutic approach for the chemoprevention and treatment of NSCLC with KRAS 
mutations.                               
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CHAPTER 1 INTRODUCTION 
1.1 Lung cancer  
Lung cancer, cancer originating in the lung or bronchus, remains the leading 
cause of cancer death in the United States and worldwide despite over 30 years of progress 
in early detection and standard treatment
1
. According to the American Cancer Society 
estimation, lung and bronchus cancers rank  the second place in new increased cases and 
accounts for the most death caused by cancer in 2012 for both female and male (Fig. 1)
2
. 
Broadly, it is divided into 2 types according to the pathology: small-cell lung cancer (SCLC) 
and non-small-cell lung cancer (NSCLC) 
3
.   
SCLC is an undifferentiated or low differentiated neoplasm composed of 
primary cell-like cells 
3,4
.  The cancer cells are usually smaller than normal cells due to 
mutations in the pathways controlling cell size. The mutations causing the uncontrolled cell 
growth majorly include retinoblastoma (RB) and P53 gene mutations 
5,6,7
. Other oncogenes 
overexpression, like c-MET, MYC and BCL2, were also strongly associated with SCLC 
5,8-10
.  
SCLC occurs almost exclusively in smokers and is highly aggressive due to the low 
differentiation grade. It is rapidly growing, and approximately 80% of patients have 
metastatic disease at the time of diagnosis 
3,4,11
.  Even though the SCLC is very responsive 
to chemotherapy and radiation therapy, such as platinum-containing agents, the tumors 
come back quickly in most patients
12
.  The mechanism of drug resistance in SCLC is 
complicated and involved multiple factors, such as membrane protein drug pumps 
overexpression, enhanced cell DNA repair system and dysfunction of apoptosis system
13-15
. 
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So SCLC is very malignant and has bad prognosis. Fortunately, it only accounts for about 15-
20% lung cancer cases (Fig.2)
1,3
.  
 
Figure 1. The estimated new cases and death caused by cancers.  
(American Cancer Society, Cancer Facts & Figures 2012. Atlanta: American Cancer Society; 
2012.) 
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Figure 2. Subtype of lung cancer 
Besides the SCLC, the most common form of lung cancer is NSCLC, which 
accounts for 80-85% of all lung tumors, including adenocarcinoma (25-35% of cases), 
squamous cell carcinoma (30–35%) and large cell carcinoma (10–15%) (Figure 2) 
3,16
. The 
three subtypes of NSCLC are divided according to the cell type of origin, but there can also 
be mixed cell types in patients. NSCLC is diverse not only in the subtype, but also in the 
genetic background
17-20
. It usually harbors a single specific mutated oncogene that is 
thought to be the primary genetic “driver” gene which leads to tumorigenesis. To date, a 
number of driver genes have been identified including: KRAS, BRAF, MEK1/2, epidermal 
growth factor receptor (EGFR), HER2, PI3K and EML4-ALK 
3,17-20
. Among those genes, 
mutation of KRAS is found in 25-30% of NSCLC
17
.  
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1.2 RAS mutations in lung cancer 
RAS gene was firstly discovered during the study of cancer-causing viruses in 
animals (Harvey JJ 1964, Kirsten 1967) 
21-22
. Then it got the name from the rat sarcoma (Ras) 
and two discoverers, Harvey ras (H-Ras) and Kirsten ras (K-Ras). There was also another Ras 
found later in human neuroblastoma cells, so called N-Ras 
23
. RAS, KRAS and NRAS all 
belong to the RAS family, which encode a family of membrane-bound 21-kd guanosine 
triphosphate (GTP)-binding proteins 
24
.   Those highly homologous proteins are all GTPases 
that act as molecular on/off switch. After binding to GTP with the help from guanine 
nucleotide exchange factors (GEFs), those RAS proteins will recruit and activate various 
downstream proteins, such as PI3K and RAF-MEK-ERK, to provide the survival and 
proliferation signals for the cells 
24-26
. Because of the intrinsic GTPase activity of RAS, it will 
hydrolyze the bound GTP into GDP with the help of GTPase activating proteins (GAPs). 
Then the GDP-bound form is inactive for downstream signaling 
24,27
.  
If there are any mutations in RAS which prevent the GTPase activity of RAS, 
the RAS will be always RAS-GTP form and constitutively active. The most common gain 
function mutations in RAS include residue G12, G13 and Q61 
28
.  The mutations at residue 
12 and 13 would attenuate the interaction of GAP to RAS and then block the hydrolysis of 
GTP by RAS protein, while the mutations at residue 61 directly abolish the hydrolysis 
activity of RAS 
28-31
. Upon those mutations, RAS proteins were constitutively “on” and the 
downstream signaling will be activated inappropriately, which can modulate cell growth, 
differentiation, and apoptosis through linked receptor and non-receptor tyrosine kinases, 
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and finally cause the tumorigenesis 
24, 29
. This is accomplished through multiple effectors 
including Mitogen-activated protein kinase (MAPK), Signal transducer and activator of 
transcription (STAT) and Phosphoinositide 3-kinase (PI3K) signaling cascades (Fig. 3) 
24-26, 32
. 
Mutations in genes which are upstream of RAS can have similar effect as well as RAS 
mutation, such as BCR-ABL or EGFR 
33-36
.                               
 
Figure 3. The RAS signaling casecades. 
RAS mutations have been found in approximately 30% of all human cancers, 
including mutations in NRAS, HRAS and KRAS 
24, 29
. Since the downstream signals of RAS 
genes vary by family members, there is some correlation between specific tumor type and 
RAS gene mutation 
29, 37
. For example, in adenocarcinoma of the lung, pancreas and colon, 
the KRAS gene is the predominantly mutated member of the RAS family, whereas in 
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myeloid leukemia it is primarily NRAS that is mutated 
38-41
.  HRAS mutations may be related 
to bladder and kidney cancers
 42-43
.  
KRAS mutations account for most of the cancer-related RAS mutations in 
NSCLCs 
38
.  The studies revealed that KRAS mutations accounts for 90% of RAS mutations in 
lung adenocarcinomas and approximately 97% of KRAS mutations in NSCLC involve codons 
12 or 13, while KRAS mutations are rare in lung squamous cell cancer 
44, 45
. Recent study 
suggests that KRAS mutations are associated with a worse overall survival in patients with 
NSCLC, especially in patients with adenocarcinoma and early stage 
46-47
. And also some 
studies suggested that the lung cancers with KRAS mutations are more resistant to 
cytotoxic chemotherapy and EGFR-TKIs treatments 
48-50
. The studies in recent two decades 
did not provide any effective way to treat the NSCLC with KRAS mutations.  
 
1.3 Lung cancer treatment 
    Symptoms of lung cancer include cough, chest pain and weight loss. However, 
many patients present with metastatic cancer having no obvious clinical symptoms. 
Diagnosis is typically made by chest x-ray or CT and confirmed by biopsy. Most NSCLC 
patients are detected when the cancer is already advanced 
51
. Depending on the stage of 
the disease, treatment may include surgery, chemotherapy, radiation therapy, or a 
combination. For the past several decades, the prognosis for a lung cancer patient was 
poor, with only 15% of patients surviving > 5 year from the time of diagnosis 
52
. For 
patients with stage IV (metastatic) disease, the 5-year overall survival rate was < 1% 
52
. 
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However, the identification of certain mutations that can be targeted for therapy, has 
recently improved outcomes.  
     Targeted therapy has been established for the treatment of advanced NSCLC, 
such as treatment with erlotinib (Tarceva) after chemotherapy, which targets the EGFR 
mutation. But since KRAS is downstream effector of EGFR, the erlotinib has little benefit for 
those NSCLC patients with KRAS mutation 
48-50
. In recent years, several new targeted 
therapies have been developed for KRAS mutation, such as the MEK1/2 inhibitor AZD6244 
(Selumetinib) 
53
, the BRAF inhibitor Sorafenib (Nexavar; BAY 43-9006) 
54
 and the Farnesyl 
Transferase Inhibitors (FTIs) 
55-56
.  
The MEK1/2 inhibitor and BRAF inhibitor function via directly binding to the 
MEK1/2 and BRAF individually and inhibiting the Kinase activity. The study on the MEK1/2 
and BRAF inhibitors showed that the combination of Selumetinib plus docetaxel as the 
second-line treatment of KRAS mutated NSCLC significantly improved outcomes. The 
primary end point of overall survival was increased from 5.2 months to 9.4 months 
57
.  A 
Phase II clinical trial of Sorafenib for the treatment of NSCLC in 2012 also showed some 
efficacy 
58
. The primary end point of overall survival from time of randomization was 13.7 
months in the treated group versus 9.0 months in placebo group 
58
.   
The FTIs can bind to farnesyl transferase (FFTase) and inhibit the farnesylation 
of KRAS on the C-terminal of protein. The post-transcription modification of KRAS, 
including farnesylation, methylation and palmitylation, will associate KRAS protein to inner 
face of the plasma membrane, which is essential for RAS interaction with other proteins 
59
. 
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Several Farnesyl Transferase inhibitors had been tested in clinical trials, including 
lonafarnib (SCH-66336), R115777 and L-778,123 
60-62
. Even those inhibitors showed the 
anti-cancer activity in pre-clinical experiments and some phase I/II studies, there was no 
improvement in overall survival in phase II/III studies 
56
. The failure of FTIs may be due to 
the alterations of farnesylation of KRAS, such as myristylation and geranylgeranylation, 
which will also associate the KRAS protein to the memberane 
63
.  
These outcomes for KRAS targeted therapy are promising but not very 
impressive. In contrast, treatment with crizotinib led to an overall survival of about 24 
months in patients with an (anaplastic lymphoma kinase) ALK rearrangement, while 
treatment with erlotinib increased overall survival to about 27 months in patients with an 
EGFR mutation 
64-65
. The KRAS targeting drugs also had some side effects, which cause 
decreased dose or interrupted dose 
66
. Toxicity concerns, together with the relatively 
modest increase in survival of current KRAS targeted therapies, highlight the urgent need 
to develop new strategies or drugs targeting KRAS mutant NSCLC. 
 
1.4 Lung cancer chemoprevention 
     KRAS mutations are not only found in cancers but also in individuals at risk 
(but without cancer) who have significant tobacco exposure and are detected in 25%–40% 
of atypical adenomatous hyperplasia lesions, which are a potential precursor of 
adenocarcinoma 
67
. This suggests that KRAS mutations exist not only in advanced NSCLC, 
but also appear to be an early event in human NSCLC development, and may be regarded 
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as the driving event of NSCLC 
67-70
. So KRAS mutations could be the good target for cancer 
chemoprevention.  
Cancer chemoprevention is the use of synthesized drugs or natural 
compounds to suppress or slow down the carcinogenesis process or prevent the 
recurrence of a tumor after successful treatment 
71
. Cancer chemoprevention represents 
an important facet of cancer research because cancer, especially late-stage cancer, remains 
the second killer in U.S.A and worldwide 
72
. Many years of research has led to great 
improvement in our understanding of the molecular mechanisms of cancer and to the 
development of various advanced treatment procedures.  However, progress has been 
slow in the long-term survival rate for patients with most solid tumors. The difficulty in 
treating late-stage cancer results from its intrinsic property: genomic instability. The 
current chemotherapy and radiotherapy may not kill 100% of the cancer cells and the 
remaining cells exhibit poor drug response, which is in part responsible for the high relapse 
rates in cancer treatment. Cancer is a multi-step disease, the development of which 
requires multiple genetic and epigenetic changes 
3, 73
. Chemoprevention targets tumor 
development at early stages, including tumor initiation and promotion when the cancer 
genome remains relatively stable. Since the most difficult obstacle in cancer treatment is 
genomic instability, bypassing it using this approach holds great potential.  
                    However, only a few molecular targets have been identified and the molecular 
basis for chemoprevention is poorly understood. To date only about 13 agents are FDA 
approved for cancer chemoprevention. They include Tamoxifen, Raloxifene, HPV vaccine, 
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Celecoxib and Fluorouracil 
74
. Tamoxifen and Raloxifene are approved to reduce the risk of 
breast cancer incidence in high-risk women 
75-76
.  The HPV vaccine is approved for the 
prevention of cervical and anal cancers caused by HPVs 
77
. Celexcoxib is a non-steroidal 
anti-inflammatory drug (NSAID) and specific COX-2 inhibitor which has been shown to 
decrease the number of adenomatous colorectal polyps in FAP patients as an adjuvant to 
regular care (such as endoscopic surveillance and surgery) 
78
. Fluorouracil (5Fu) is used as a 
chemotherapy drug to treat several types of cancer including colon, rectum, and head and 
neck cancers. It was recently approved by the FDA for topical treatment of actinic keratosis 
(AKs) 
79
. Untreated AKs can become squamous cell carcinomas (SCC), the second most 
common form of skin cancer. In addition to these approved drugs, more agents are being 
investigated in labs for use in chemoprevention 
74, 80-82
. Phytochemicals, including 
curcurmin and genistein, represent a popular class of potential chemoprevention agents 
83-
84
. Based on epidemiological studies, it has been demonstrated that these compounds have 
anti-inflammatory activities and can reduce the risk of carcinogenesis 
85
.  
                    Despite the handful of FDA approved chemoprevention drugs, there are still a 
lot of difficulties in current chemoprevention strategies. For those phytochemicals, the 
mechanism of anti-inflammatory activity remains unclear. Without a precise assessment of 
the mechanisms, it is unlikely that phytochemicals will be recommended for testing in 
human clinical trials. Even for those approved chemoprevention drugs; successful 
treatment requires long-term administration, which can lead to toxicity, high cost and 
resistance. For lung cancer, some agents, such as COX2 inhibitors, have shown activity 
against lung cancer in animal 
86
. However, in clinical trials the effect is not very obvious and 
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long-term continuous administration is required, which causes safety concerns 
87
. Even the 
approved chemoprevention drugs, Tamoxifen and Raloxifene, achieved 50-70% reduction 
in incidence of invasive breast cancer in the treatment arm, toxicity and resistance are still 
notable concerns 
74,
 
88
. In an effort to overcome these challenges, we need to develop new 
chemoprevention approaches that can specifically target premalignant tumor cells or 
malignant tumors. 
                      In the lung cancer field, there are also some drugs and methods being studied 
specifically targeting chemoprevention. Several natural products have been tested in 
clinical trials for lung cancer chemoprevention in smokers, including beta-carotene, retinol, 
Vitamin E or N-acetylcysteine 
89-93
.  Unfortunately, these trials showed either neutral or 
harmful primary endpoint results in primary, secondary or tertiary prevention 
89-93
. Trials of 
aspirin and selenium also had little to no positive effect 
94-95
. Recently, there have been a 
number of studies focused on NASIDs for lung cancer chemoprevention, particularly the 
COX-2 inhibitors 
96-97
. This is because inflammation has been correlated with carcinogenesis 
and COX-2 over-expression has also been observed in former smokers. Additionally, COX-2 
over-expression is shown to be a poor prognostic indicator in NSCLC 
98-99
.  The most well-
known COX-2 inhibitor is celecoxib, which inhibits the production of PGE2 and reduced the 
Ki-67 labeling index in active smokers in a phase II clinical trials 
100
.  However, the large 
scale chemoprevention trials of celecoxib had only neutral results 
96-97
. There is still no 
clear path for the development of lung cancer specific chemoprevention strategies. 
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1.5 SITEP based cancer chemoprevention 
For most traditional approaches of chemoprevention, it usually applies the 
agents to modulate the tumorigenic pathways rather than eliminate large numbers of 
premalignant or malignant cells, which will also affect the normal cells 
101
. To keep the 
toxicity to the minimum or the lowest tolerated level of patients, only very limited dose of 
agents had been applied for chemoprevention, which will lead to low efficacy. To maintain 
the efficacy of chemoprevention, long term continuous or near continuous treatment could 
not be avoided, which will cause the accumulated toxicity and bring some unexpected side 
effects.  
 In contrast to those traditional long term and continuous dosing treatment 
for chemoprevention, a new idea called short-term intermittent therapy to eliminate 
premalignancy (SITEP) has been raised based on the synthetic lethality strategy 
102
. The 
core goal of SITEP is to reduce the long-term toxicity, while maximizing efficacy, by using 
short term and intermittent treatment to prevent cancer. This goal can be achieved 
because of the nature of carcinogenesis. Carcinogenesis is a multistep process that involves 
the accumulation of many genetic and epigenetic changes 
3, 73, 89
. Typically only a few 
crucial mutations will drive normal cells to become premalignant cells and finally malignant 
cells. The SITEP approach is to kill the premalignant cells by targeting the crucial mutations 
via short term and intermittent treatment. Intermittent treatment can reduce the number 
of premalignant cells and ultimately decrease the patient’s risk of developing cancer 
between treatment cycles (Fig 4).  
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Figure 4. The principle of SITEP. The number of premalignant tumor cells is 
positively proportional to the cancer risk in patients. Intermittently eliminating 
premalignant tumor cells with short time treatment should dramatically decrease 
the cancer risk and subsequently inhibit or delay cancer development.   
(Xiangwei Wu and Scott M. Lippman, Nature Reviews:Cancer, 2011, vol 11) 
 
1.6 Synthetic lethality 
                        One of the key factors for SITEP is to eliminate a large numbers of 
premalignant cells by a short term treatments.  That requires potent and selective killing 
effects on the premalignant cells in a short time. Synthetic lethality might be an 
appropriate strategy for that purpose. 
Synthetic lethality means the cell death could be induced by the combination 
of mutations in two or more sensitive genes, while mutation of single gene alone is not 
sufficient to induce cell death 
102
.  Compared to the current cytotoxic drugs, the synthetic 
lethality approach has the advantage of inducing apoptosis selectively and precisely in 
those mutated cells while not harming the normal cells. Compared to the current targeted 
therapy drugs, such as the kinase inhibitors or antagonists, synthetic lethality has the 
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advantage of changing the targeting effect from cytostatic to cell death, which is more 
efficient and less toxic.  Based on the idea of synthetic lethality, it is recently reported that 
apoptosis could be induced specifically in the premalignant cells with particular gene 
mutations, BRCA1/2 mutation 
103
. Poly (ADP-ribose) polymerase (PARP) inhibitors hinder 
base-excision repair and cause cell death in BRCA1/2 deficient cells due to DNA damage 
and could be used to target the BRCA1/2 mutant breast premalignant cells.  Our lab also 
reported that Retinoic Acid (RAc) plus TRAIL, which targets the APC deficient colorectal 
premalignant cells, have the potential to be effective chemopreventive agents 
104
.  RAc plus 
TRAIL induces apoptosis only in the APC deficient cells due to the up-regulated cMyc level, 
resulting in reduced cFLIP levels, will sensitize the cells to TRAIL triggered extrinsic 
apoptosis. The outcome of animal experiments with APC/Min mice has proved the great 
potential for chemoprevention.  
 
1.7 Apoptotic pathway and TRAIL 
Apoptosis is one type of Programmed Cell Death (PCD) which exists in 
difference organisms 
105
. It is usually characterized by distinct morphological changes, 
energy-dependent biochemical cascades and finally cell 
105-106
. The morphological changes 
include membrane blebbing, cell shrinking, chromatin condensation, 
and chromosomal DNA fragmentation 
105-106
. The intrinsic biochemical processes include 
activation of caspase cascades, protein cleavage, protein cross-linking and DNA breakdown 
105-107
.   
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                     Caspases are a family of proteases which are able to cleave proteins at aspartic 
acid residues
 108
.  So far about 10 caspases have been identified and categorized into 3 
groups. They are initiators (caspase-2,-8,-9,-10), effectors or executioners (caspase-3,-6,-7) 
and inflammatory caspases (caspase-1,-4,-5) (14). Pro-caspases can be activated through 
either intrinsic or extrinsic apoptotic pathways by cleavage 
108-109
. The intrinsic apoptotic 
pathway activates caspases via permeabilization of the mitochondria and release of pro-
apoptotic proteins into the cytoplasm, such as cytochrome c, Apaf-1 and second 
mitochondria-derived activator of caspase (Smac) 
110-112
. Cytochrome c and Apaf-1 form a 
multi-protein complex known as the “apoptosome” and initiate activation of the caspase 
cascade through cleavage of caspase-9 
111
. The extrinsic apoptotic pathway activates the 
caspases via transmembrane death receptors such as tumour necrosis factor receptor 1 
(TNFR1), Fas/CD95 and TRAIL receptors (DR4/5) 
112-113
. As death ligands bind to these 
receptors, the death inducing signaling complex (DISC) is formed leading to initiation of the 
caspase cascade through cleavage of caspase-8/10 
114
. Once caspase-8/10 is activated, the 
downstream caspases are triggered, and the cell undergoes apoptosis 
112-114
.  
                       Researchers observed apoptotic cells in different cancers and found that a 
high rate of apoptosis is correlated with slow growing tumors, and increased apoptosis was 
also observed in tumors treated with radiation or chemotherapy 
115
. Elsewhere, 
researchers reported that failure of apoptotic activation may promote cancer growth and 
even cause 
116-117
. This may be the case in tumors with Bcl-2 overexpression not only 
survives the removal of growth factors, but is also resistant to chemotherapy 
116
. Taken 
together, this indicates that induction of apoptosis may be an interesting approach for 
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cancer treatment. Agents that can restore the apoptotic signaling pathways may 
specifically kill the cancer cells, which require these apoptotic defects to survive. A lot of 
studies have focused on these agents, which has opened the door into a new type of 
anticancer drugs and treatment strategies 
118-120
. This class of drugs includes Bcl-2/Bcl-xL 
inhibitors, Bcl-2/Bcl-xL siRNA, XIAP siRNA and caspase activating drugs. Among them, the 
death receptor ligand tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) 
is a popular candidate and has great potential 
116
.  
                     TRAIL was first cloned in the 1996 
121
 and following studies showed that TRAIL 
forms a homotrimer and binds to its death receptors 4 and 5 (DR4, DR5) on the cell surface 
122
. Both DR4 and DR5 have 2 extracellular cysteine-rich domains and one cytoplasmic 
death domain (DD) 
122
. Upon binding to TRAIL, DR4 and DR5 also form homotrimers or 
heterotrimers and recruit Fas-associated death domain (FADD) through the DD interaction 
123-124
. Then FADD recruits amino terminal death effector domain (DED)-containing 
apoptosis initiating proteases, caspase-8/10 via its own DED domain 
123-124
. The cytoplasmic 
DD domain of DR4/5, the FADD and the caspase 8/10 form a death-inducing signaling 
complex (DISC) 
123-124
.The formation of DISC will cause caspase-8/10 auto-cleavage and 
active, which will trigger the downstream process including cleavage of downstream 
effector caspase-3/7 and DNA fragmentation
 125
.  In addition to DR4 and 5, three decoy 
receptors of TRAIL, DcR1, DcR2 and OPG, can also interact with TRAIL. These decoy 
receptors may exist in both membrane-bound and soluble form 
126
. When bound to the 
membrane, the lack of functional cytoplasmic signaling domains will block the TRAIL 
induced death signaling 
126
. Upon TRAIL binding to DR4 or DR5, death receptor mediated 
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apoptosis can be inhibited by a protein called cellular FADD-like IL-1β-converting enzyme 
(FLICE)-like inhibitory protein (c-FLIP),  which binds to FADD and pro-caspase 8/10 and 
prevents the cleavage of pro-casepase 8/10 (Fig.5) 
127
.  
                                              
                        Figure 5. The intrinsic and extrinsic apoptotic pathways of TRAIL     
                   In recent years, TRAIL has shown the great potential as an anti-tumor candidate 
by selectively killing a wide variety of human tumor cell lines without harming normal cells 
125
. This discovery resulted in the rapid development of cancer therapeutics targeting this 
pathway. The TRAIL pathway has been targeted for clinical application by at least two 
approaches: recombinant human TRAIL (rhTRAIL) ligand and agonistic antibodies against 
DR4 and DR5 
126-129
. The toxicity of rhTRAIL and the DR4/DR5 monoclonal antibodies 
(Mapatumumab and Apomab) has been evaluated in a variety of animal assays, with little 
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or no toxicity 
128-129
. Both rhTRAIL and TRAIL agonists have been moved to in phase II 
clinical trials 
125
. TRAIL showing low toxicity to normal cells usually depends on the 
overexpression of decoy receptors to prevent TRAIL–induced apoptosis by either binding 
competition or another mechanism 
130
. Tumor cells frequently develop strategies to resist 
TRAIL induced apoptosis, including overexpression of decoy receptor, cFLIP and Inhibitors 
of Apoptosis Protein (IAPs) 
131-134
.   
 
1.8 IAPs and Smac 
IAPs belong to a family of proteins which inhibit caspase activation by binding to 
them and preventing cleavage of their substrates. All IAPs consist of one or more 
baculoviral IAP repeat (BIR) domains while some IAPs also contain a RING domain which 
acts as an E3 ubiquitin ligase. X-linked inhibitor of apoptosis (XIAP) and cIAP1/2 are 
examples of RING domain containing IAPs. The most well characterized mammalian IAP is 
XIAP, which can bind to and inhibit caspases-3, -7 and -9 via its BIR domains (Fig. 6) 
135
.  
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                                           Figure 6. The family of IAPs in mammalian cells 
(Stefan J. Riedl and Yigong Shi, Nature Reviews:Molecular Cell Biology, 2004, Vol 5) 
                    
 To overcome the blockade of IAPs, TRAIL-induced extrinsic apoptotic pathway 
therefore requires help from the intrinsic mitochondrial pathway via caspase-8 cleavage of 
BH3 interacting domain death agonist (Bid) 
136
. Truncated Bid (tBid) can interact with Bax 
and Bak and induces the oligomerization of Bax and Bak in the mitochondrial membrane, 
which leads to activation of the intrinsic apoptotic pathway and release of Smac from the 
mitochondria 
136
. Smac subsequently binds to the BIR domain of the IAPs, relieving the 
blockade and leading to apoptosis 
137-138
.  
                        Smac is a 25-kDa protein which is expressed in mitochondria and is released 
during the apoptosis 
139
. Experiments using recombinant proteins have shown that caspase 
inhibition by IAPs can be relieved by the addition of IAP antagonist in vitro 
140.
 Hence the 
molecules that mimic the binding interactions between IAPs and Smac, referred to as Smac 
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mimetics, are being designed as a novel class of anticancer drugs through targeting IAP 
proteins, and thus sensitizing cells to induction of apoptosis.  So far there have been 
numerous reports showing that different Smac mimetics have strong anticancer activities 
141-145
. Several Smac mimetics are being tested in clinical trial, such as TL32711 in phase I 
study of adult patients with advanced solid tumors and lymphoma 
141
. For this drug, no 
dose-limiting toxicities have been observed and there is strong evidence of anti-tumor 
activity. Other Smac mimetics being tested include LCL161 (Novartis) 
142
, GDC-0917 
(Genentech) 
143
, HGS1029 (Human Genome Sciences) 
144
 and AT-406 (Ascenta)
 145
. Our lab 
received Smac mimetics JP1584 from Joyant Pharmaceuticals (Dallas, TX) as a gift. The 
JP1584 is a small molecule and the secondary generation of Smac mimetics developed by 
Joyant Pharmaceuticals. It is derived from the first generation of Smac mimetics JP1010, 
which is a synthesized dimeric peptide (Fig. 7)
146
.   
 
Figure 7. The Chemical structures of JP1010.  
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1.9 Statement of problem, hypothesis and project goals 
                Lung cancer is the leading cause of cancer death in both
 
men and women in the 
United States. Despite improvement in treatment strategies, the 5-year survival rate of 
lung cancer patients remains low. Thus, effective
 
chemoprevention and treatment 
approaches are sorely needed.  
                  Recently our lab published a paper in Nature, which reported a synthetic lethal 
interaction between TRAIL, RAc and the APC gene (Fig. 5) 
104
. We showed that TRAIL and 
RAc cooperatively induced apoptosis in APC-deficient cells without harming normal cells. 
Furthermore, short-term treatment with TRAIL plus RAc significantly reduced polyp 
numbers by up to 90% in APC-deficient mice. These results suggest that the combination of 
TRAIL and RAc have great potential in eliminating premalignant tumor cells and preventing 
tumor-related death in these animals.  
                  The APC-deficiency mediated cMyc up-regulation is the key factor that sensitizes 
the cells to TRAIL plus RAc combination treatment.  It was also reported that KRAS 
activation can up-regulate cMyc 
147
.   Considering the fact that mutations and activation of 
KRAS occurs frequently in NSCLC and these changes are thought to be primary drivers for 
lung carcinogenesis, I hypothesized that the premalignant lung cells and lung cancer cells 
with KRAS mutations could be specifically targeted for TRAIL induced apoptosis (Fig.8).  
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Figure 8. Synthetic lethal interaction between TRAIL, RAc, Smac mimetic and KRAS  
                  The Inhibitors of Apoptosis Proteins (IAPs) in those cells with abnormal KRAS 
activation are usually up-regulated to antagonize apoptosis. The blockade can be overcome 
by the Smac mimetics, as reported in the literature 
132
. Since KRAS mutation is also 
preserved in malignant stages, it is reasonable to propose that combination treatment 
could also be efficacious in the treatment of cancer.  
                   Pursuing a new approach to specifically kill premalignant cancer cells would 
enable us to develop a more effective strategy for cancer prevention. In this way, we could 
make chemoprevention work like therapy to reduce the duration of treatment.  The SITEP 
approach, applying synthetic lethality to target KRAS dys-regulation, will also minimize the 
potential side effects and reduce the costs associated with long-term therapy.   
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                  Given this information, we hypothesize that the co-treatment of TRAIL, RAc and 
Smac mimetic will induce a synthetic lethal interaction specifically in the mutant-KRAS cells, 
and that this approach may be applied as a new method to prevent and treat NSCLC with 
KRAS mutation. 
  
  
24 
 
CHAPTER 2 MATERIALS AND METHODS  
2.1 Cell culture 
                   The immortalized human bronchial epithelial (HBE) cell line HBE4-E6/E7 (HBE4) 
was purchased from ATCC. BW1799 cells were kindly provided by Dr. Reuben Lotan of M.D. 
Anderson Cancer Center and were maintained in Keratinocyte-SFM medium (Life 
Technology, Grand Island, NY). Lung cancer cell lines NCI-H322, NCI-H661, NCI-H460, NCI-
H358, NCI-H157, A549, NCI-H2122 and NCI-H1299 were all purchased from ATCC and 
maintained in RPMI 1640 medium (Thermo Scientific , Rockford, IL) supplemented with 10% 
Fetal Bovine Serum (FBS) and 1% antibiotics (penicillin/streptomycin).  
 
2.2 Plasmids, shRNAs, and reagents 
                     The retroviral plasmid expressing a mutant KRAS (KRASV12) was reported in 
previous paper 
156
 and generously provided by Dr. Jinsong Liu from UT M.D. Anderson 
Cancer Center. ERK dominant-negative and AKT/PKB dominant-negative constructs were 
generously provided by Dr. Mien-Chie Hung from UT M.D. Anderson Cancer Center. The 
long form c-FLIP construct was generated in pcDNA3.1 (Life Technology, Grand Island, NY) 
by cloning cellular c-FLIP cDNA from total RNA of Hela cells, as previously reported 
136
.The 
DR5 expression plasmid was provided by W. El-Deiry. The c-Myc-shRNA was generated in 
pSUPER and the target sequence is 5’-TTCAAGAGA-3’ 
104
. XIAP-shRNA was purchased from 
Open Biosystems. Recombinant soluble rhTRAIL protein was purified according to 
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published methods
157
. In the purification, the B-PER buffer and Ni-NTA agarose were 
purchased from Thermo Scientific 
146
. The Fluorouracil (5Fu) was purchased from Sigma (St. 
Louis, MO).  U0126 and Wortmannin were purchased from CalBiochem (Billerica, MA). 
 
2.3 Antibodies 
                       Anti–c-FLIP monoclonal antibody was purchased from ALEXIS Biochemicals 
(Farmingdale, NY). Anti–phospho-ERK, anti–phospho-AKT, anti–cleaved CASPASE 3, anti-
CASPASE 8 and anti-DR5 antibodies were purchased from Cell Signaling Technology 
(Danvers, MA). Anti–c-MYC and Anti-DR4 antibody was purchased from Millipore (Billerica, 
MA). Anti–β-Actin and anti–α-TUBULIN antibodies were purchased from Sigma (St. Louis, 
MO). Antibodies against DCR1 and DCR2 were purchased from Imgenex (San Diego, CA). 
Anti-XIAP, anti-BCL2 and anti-BCL-XL antibodies were purchased from BD Transduction 
Laboratories (San Jose, CA). 
 
2.4 Infection, transfection, and drug treatment 
                       Retrovirus was generated by using the BOSC23 packaging cell line, and 
infection was carried out as reported previously 
158
. Transfections were carried out by using 
Lipofectamine 2000 (Life Technology, Grand Island, NY) according to the manufacturer’s 
instructions. For TRAIL and Smac mimetic treatment, cells growing in log phase were 
treated with Smac mimetic at a final concentration of 100nmol/L for 30 minutes. Then 
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TRAIL was added to the media at a final concentration of 100ng/mL.  For 5-Fu treatment, 
cells growing in log phase were treated with 5-Fu at a final concentration of 5ug/mL for 12-
16 hours. Cells were harvested after 24 hours of TRAIL treatment. Where indicated, cells 
were treated with Wortmannin (200 nmol/L) and U0126 (10 mmol/L) for 30 minutes. Cell 
viability was determined by using Annexin V-FITC Apoptosis Detection Kit (Sigma, St. Louis, 
MO) according to the manufacturer’s instructions. 
 
2.5 Mouse Model for Tumorigenesis 
                Breeding colonies were established from LSL-Kras
G12D
 mice acquired from the 
Mouse Repository of the National Cancer Institute. AdenoCre virus was purchased from the 
Gene Therapy Core of Baylor College of Medicine. Mice were infected according to a 
previously reported protocol 
159-160
. In brief, AdenoCre-calcium phosphate (AdCre-CaPi) 
precipitates were prepared by placing recombinant adenovirus in 1 mL of Eagle’s minimal 
essential media containing 1.8 mmol/L Ca
2+
 and 0.86 mmol/L Pi. Then an aliquot of a 2 
mol/L CaCl2 solution was added to achieve a concentration of 4.5 mmol/L Ca
2+
. The 
solution was mixed by vortex or gentle pipetting, and the mixture was allowed to incubate 
for 20 to 30 minutes at room temperature. G12D mice were anesthetized with avertin at 8-
12 weeks of age. AdCre-CaPi coprecipitates [5 - 10
8
 pfu (plaque forming units)] were 
administered intranasally in two 62.5-µL instillations. The second instillation was 
administered when breathing rates had returned to normal following the first 
administration. Six weeks after infection, the mice were injected intravenously with Smac 
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mimetic (3 mg/kg). Six hours later, TRAIL (3 mg/kg) was administerd by intraperitoneal (i.p.) 
injections. This regimen was repeated 18 hours later. Consecutive injections of TRAIL and 
Smac mimetic were given a total of 3 times. Injection of PBS was used as a control. For 
intermittent treatment, the mice were given 3 consecutive injections of TRAIL and Smac 
mimetic (1.5 mg/kg) within a week, left off treatment for 3 weeks, followed by another 
week of injections, for a total of 3 treatment cycles. The mice were sacrificed 1 day after 
the last treatment, and their lungs were inflated with formalin and fixed in formalin 
overnight.  
                     For the xenograft model, male athymic nude mice aged 2 months were 
purchased from Jackson Labs. The nude mice were inoculated subcutaneously at the right 
flank with 1 x 10
6
 NCI-H322, or NCI-H460 cells in 100 μl of PBS 
161
. Treatment was started 
once the solid tumor reached 5 mm, mean diameter (about 12 days after NCI-H322 or NCI-
H460 incubation). In treated group, 3 mice were injected intravenously with Smac mimetic 
(3 mg/kg). Six hours later, TRAIL (6 mg/kg) was injected i.p.. Injections were repeated 18 
hours later. Consecutive injections of TRAIL and Smac mimetic were given every another 
day for a total of 6 treatments. To minimize measurement variability, tumors were 
measured every 3 days, by a single individual using the same calipers. Tumor volume was 
calculated using the following formula: V (mm
3
) = [width
2 
(mm) x length (mm) x π]/6. On 
day 24, mice were sacrificed and tumors were fixed in formalin overnight. All animal 
experiments were conducted according to the ethical standards of the U.T.MD Anderson 
Cancer Center Animal Care and Use Committee (ACUC).   
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2.6 HE and IHC staining 
                       Lung sections were analyzed by hematoxylin and eosin (HE) and 
immunohistochemistry (IHC) staining using an anti–cleaved caspase 3 antibody. Tissue 
sections were de-paraffinized and rehydrated in an ethanol series. For HE staining, sections 
were stained in Mayer’s hematoxylin solution (Sigma, St. Louis, MO) for 2 min, then rinsed 
in 0.1% HCl-ethanol solution for 2 sec. The differentiation will take about 5 min in running 
tap water.  Then the sections were stained in eosin Y solution 0.1% aqueous (Sigma, St. 
Louis, MO) for 3-5 min and rinsed in tap water for 30-45 sec. After checking the staining 
quality under the microscope, the sections were dehydrated again and mounted with 
mounting medium (Vector labs, Burlingame, CA). For IHC staining, the sections were 
blocked for non-specific binding with 5% goat serum and incubated with the primary anti-
cleaved caspase 3 antibody for overnight at 4°C. On the second day, the sections were 
incubated with biotinylated secondary antibody for 1 hour at 37°C and then 
Avidin/Biotinylated HRP complex (Vector labs, Burlingame, CA) for 1 hour at 37°C. The DAB 
development were operated with the DAB Kit (Vector labs, Burlingame, CA) according to 
the manufactory instructions. 
 
2.7 TUNEL assay 
Apoptosis in tumor sections was analyzed using Terminal deoxynucleotidyl 
transferase dUTP nick end labeling (TUNEL) staining with the kit from Sigma (St. Louis, MO).  
Tissue sections were de-paraffinized and rehydrated in an ethanol series. Pre-treat the 
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sections with proteinase K solution from the kit and incubate the sections with TdT 
reaction mixture for 1 hour at 37°C. Stop the reaction with stop solution and rinse the 
sections with PBS. Finally the sections were counterstained with 4’,6’-diamidinio-2-
phenylindole (DAPI) and mounted with Vectashield hard set mounting medium (Vector labs, 
Burlingame, CA). 
 
2.8 Statistical analysis 
                       We compared differences between groups via 1-way ANOVA. Values with a P 
< 0.05 were considered to be statistically significant. 
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CHAPTER 3  Use TRAIL and Smac mimetic for lung cancer    
chemoprevention 
      KRAS mutations are found in individuals who have significant tobacco 
exposure and also detected in 25-40% atypical adenomatous hyperplasia lesions, which 
suggests that KRAS mutations is an early event in human NSCLC development. And also it is 
reported that KRAS is one of the most important driver genes in NSCLC tumorigenesis 
19
. So 
we targeted KRAS mutations for NSCLC chemoprevention. In this chapter, first I tested the 
response of normal lung epithelial cells with KRAS activation to TRAIL and Smac mimetic. 
Then I dissected the molecular basis behind the response. After confirming the effect of 
TRAIL and Smac mimetic co-treatment in vitro, I also evaluate the efficacy of the TRAIL and 
Smac mimetic co-treatment in vivo within the LSL–K-RAS G12D mice. 
 
3.1 TRAIL and Smac mimetics specifically induce apoptosis in KRAS-activated HBE4 and 
BW1799 cells. 
                        To test if TRAIL and Smac mimetics combination can eliminate the 
premalignant lung cells, we need to establish an in vitro model of the premalignant lung 
cancer cells. So here we introduced the activating mutant KRAS
G12V
 into the immortalized 
normal lung epithelia cell lines HBE4 and BW1799. Signaling downstream of KRAS, 
including Erk and AKT, was increased following constitutive expression of mutant KRAS in 
HBE4 and BW1799 cell lines (Fig. 9A). Then, to test whether KRAS activation sensitizes 
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normal lung epithelial cells to TRAIL plus Smac mimetics–induced apoptosis, HBE4 cells 
transfected with vehicle or mutant KRAS plasmid were treated by Smac mimetic for 30min, 
then followed by TRAIL treatment or by Smac mimetic or TRAIL treatment individually. 
After 24 hours post TRAIL treatment, the apoptotic cells were determined with annexin V-
FITC apoptosis detection kit. Results showed that HBE4 cells transfected with vehicle 
plasmid are resistant to apoptosis induced by TRAIL, Smac mimetic or the combination (Fig. 
9B), while cells transfected with mutant KRAS are sensitive to TRAIL plus Smac mimetic–
induced apoptosis but not the single treatment (Fig. 9B). Similar results were observed in 
BW1799 cells (Fig. 9C). These results indicate that activation of KRAS specifically sensitizes 
normal lung epithelial cells to the induction of apoptosis by the combination of TRAIL and 
Smac mimetic.  
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Figure 9. Mutant KRAS activates downstream-signaling pathways and sensitizes 
normal cells to TRAIL and Smac mimetics. A, overexpression of mutant KRAS and 
induction of phosphorylation of ERK (p-ERK) and AKT (p-AKT) in BW1799 and HBE4 
cells. These cells were infected with either vehicle retrovirus (Vec) or mutant KRAS 
expressing-retrovirus. B&C, induction of apoptosis by TRAIL and Smac mimetics. 
HBE4 cells and BW1799 cells expressing mutant KRAS were treated with TRAIL 
(100 ng/mL) or Smac mimetics (100 nmol/L) or both or control (PBS) for 24 hours. 
Apoptotic cells (Annexin V
+
/PI
-
) were counted. The data represent results from 3 
independent experiments. Averages and SD are shown.  
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3.2 Mutant KRAS up-regulates TRAIL receptor levels to facilitate TRAIL-induced 
apoptosis in normal cells. 
                 Even we hypothesize the synthetic lethality will be generated by combination of 
TRAIL, RAc and Smac mimetic, previous results showed that the combination of TRAIL and 
Smac mimetic can induce apoptosis in the normal lung epithelial cells with KRAS activation 
independent of RAc.  Then I tested the role of RAc in normal lung epithelial cells as well as 
APC deficient colon cells. The results showed that RAc is not essential for TRAIL plus Smac 
mimetic–induced apoptosis (Fig. 10A). This suggests that KRAS may modulate the 
expression of TRAIL receptors as RAc does in the APC deficient colon cells. I tested this 
possibility by examining TRAIL receptor expression by Western blot. Expression of mutant 
KRAS induced the expression of DR4 and DR5 (Fig. 10B). Mutant KRAS also significantly 
inhibited the expression DcR2 (Fig. 10B). These results indicate that expression of mutant 
KRAS enhances the DR4/5 expression while repressing the DcR1/2 expression, which 
facilitates TRAIL signaling. In other words, mutant KRAS exerts a similar effect on TRAIL 
receptors to that of RAc and thus eliminates the need for adding RAc to TRAIL plus Smac 
mimetic for the induction of apoptosis in mutant KRAS cells.  
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Figure 10. Modulation of TRAIL-receptor expression by KRAS. A, RAc did not 
enhance TRAIL- and Smac mimetics–mediated apoptosis in HBE4 cells expressing 
mutant KRAS. B, Effect of KRAS activation on the TRAIL receptors DR4, DR5, DcR1, 
and DcR2. HBE4 cells were infected with either vector or mutant KRAS-expressing 
retrovirus. 
 
3.3 Sensitization to TRAIL plus Smac mimetic mainly depends on the activation of the 
MAPK/ERK pathway. 
                    KRAS functions as an upstream activator of RAF-MEK-ERK and PI3K-Akt signaling 
pathways, which both can up-regulate the cMyc 
25-26
. The activation of KRAS signaling may 
sensitize normal bronchial epithelial cells to apoptosis induced by TRAIL and Smac mimetic 
via cMyc activation. To investigate the role of two major KRAS downstream signaling 
pathways (activation of ERK through RAF and of AKT through PI3K) in contributing to TRAIL 
plus Smac mimetics–induced apoptosis in mutant KRAS cells, I used MAPK/ERK and AKT 
inhibitors or dominant-negative mutants to block the signaling pathways in HBE4-KRAS 
stable cells. Induction of dominant-negative mutants of ERK1/2 inhibited KRAS-mediated 
ERK activation and TRAIL plus Smac mimetics–induced apoptosis; similarly, U0126, a MEK 
inhibitor upstream of ERK, also blocked TRAIL plus Smac mimetics–induced apoptosis via 
inhibition of ERK activation (Fig. 11A and 11B). The inhibition of AKT activation by either 
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the AKT dominant-negative mutant or Wortmannin, a PI3K inhibitor upstream of AKT, did 
not attenuate TRAIL plus Smac mimetics–induced apoptosis (Fig. 11A and 11B). These 
results indicate that the sensitization to TRAIL plus Smac mimetics-induced apoptosis is 
primarily dependent on activation of the MAPK/ERK pathway. 
 
Figure 11. The ERK/MAPK pathway is essential for KRAS-mediated sensitization. 
A, inhibition of KRAS-mediated activation of ERK and AKT. Phosphorylated ERK (p-
ERK) and AKT (p-AKT) were assessed in HBE4-KRAS cells transfected with a 
dominant-negative AKT mutant (AKTDN) or ERK1/2 dominant-negative mutants 
(ERKDN) or vector (control), or in these cells treated with the PI3K inhibitor 
Wortmannin (200 nmol/L) or the dual MEK1 and MEK2 inhibitor U0126 (10 
mmol/L) or control (dimethyl sulfoxide, DMSO). B, TRAIL- and Smac mimetics–
mediated apoptosis was attenuated by ERKDN and MEK1/2 inhibitors. The 
dominant-negative mutant transfected or inhibitors treated HBE4-KRAS cells were 
treated with TRAIL and Smac mimetics for 24 hours. Apoptotic cells (Annexin 
V
+
/PI
-
) were counted. The data represent results from 3 independent experiments. 
Averages and SD are shown.  
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3.4 Sensitization to TRAIL plus Smac mimetic in oncogenic KRAS–expressing normal 
epithelial cells is dependent on the regulation of c-Myc and c-FLIP levels. 
                   Even though previous results indicate that the sensitization to TRAIL plus Smac 
mimetics-induced apoptosis is primarily dependent on activation of the MAPK/ERK 
pathway, we still do not know if the MAPK/ERK activation regulate the expression of c-Myc, 
which in turn inhibits the expression c-FLIP to sensitize cells to TRAIL and Smac mimetics. 
So I first analyzed the expression of c-Myc and c-FLIP in mutant KRAS cells. As we predicted, 
expression of mutant KRAS resulted in increased levels of c-Myc protein and consequently 
decreased levels of c-FLIP protein expression (Fig. 12A). I then sought to confirm the 
significant role of c-Myc and c-FLIP in sensitization to TRAIL plus Smac mimetic. To this end, 
c-Myc-shRNA was transfected into mutant KRAS cells to knock down c-Myc expression. The 
transfection abolished KRAS-mediated induction of c-Myc expression and restored c-FLIP 
expression (Fig. 12B). More importantly, knockdown of c-Myc significantly inhibited TRAIL 
plus Smac mimetics–induced apoptosis (Fig. 12D). Furthermore, restoring c-FLIP expression 
by transfecting a c-FLIP–expression plasmid blocked TRAIL plus Smac mimetics–induced cell 
death in mutant KRAS cells (Fig. 12C and 12D). These data support the ability of KRAS to 
sensitize normal HBE4 cells to TRAIL and Smac mimetics through activation of c-Myc and 
the subsequent repression of c-FLIP expression.  
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Figure 12. c-MYC and c-FLIP are involved in TRAIL plus Smac mimetics–induced 
apoptosis in mutant KRAS–expressing cells. A, mutant KRAS activates c-MYC and 
represses c-FLIP. HBE4 cells were infected with either control or KRAS-expressing 
retrovirus. B, c-MYC was knockdown in mutant KRAS-expressing cells. HBE4 cells 
were infected with either control or KRAS-expressing virus or were transfected 
with c-Myc-shRNA after KRAS infection. C, c-FLIP is overexpressed in in mutant 
KRAS-expressing cells. HBE4 cells infected with KRAS were transfected with either 
control vector or full length c-FLIP plasmid. D, apoptosis was attenuated by cMYC 
knockdown or cFLIP overexpression. HBE4 cells with various infection and 
transfection combinations were treated with TRAIL and Smac mimetics. Apoptotic 
cells (Annexin V+/PI-) were counted. The data represent results from 3 
independent experiments. Averages and SD are shown.      
. 
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3.5 Smac mimetic overcomes the antiapoptotic activity of XIAP to facilitate TRAIL-
induced apoptosis. 
                        Previous results had shown that not the single TRAIL or Smac mimetic but 
only the TRAIL plus Smac mimetic combination can induced the apoptosis in mutant KRAS 
cells. We hypothesize that Smac mimetic could bind to IAPs, release the caspases and 
sensitize the mutant KRAS cells to TRAIL induced the apoptosis. But it is also reported that 
Smac mimetic could activate NF-κB pathway and increase the autocrine TNFα level which 
may also trigger the apoptosis 
148-149
.  So I next examined the target of Smac mimetic in 
sensitizing mutant KRAS cells to TRAIL. I first analyzed XIAP expression in mutant KRAS cells 
by Western blot. Although expression of XIAP was not significantly affected by mutant 
KRAS, significantly high levels of XIAP were detected, suggesting that the anti-apoptotic 
activity of XIAP needed to be inhibited to facilitate TRAIL induced apoptosis (Fig. 13A). To 
investigate this possibility, I used XIAP-shRNA to inhibit the expression of XIAP in mutant 
KRAS cells (Fig. 13A). Knockdown of XIAP sensitized mutant KRAS cells to TRAIL-induced 
apoptosis (Fig. 13B), in the absence of Smac mimetic. These results support the role of 
Smac mimetic in targeting the anti-apoptotic activity of XIAP to facilitate TRAIL induced 
apoptosis. This sensitization is independent of intrinsic pathway of apoptosis. 
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Figure 13. Role of XIAP in TRAIL plus Smac mimetics–induced apoptosis in 
oncogenic KRAS–expressing cells. A, effect of XIAP knockdown. HBE4 cells were 
infected with either control or mutant KRAS-expressing virus or were transfected 
with XIAP-shRNA after KRAS infection. B, induction of apoptosis. HBE4 cells with 
various infection and transfection combinations were either treated with TRAIL or 
not treated. Apoptotic cells (Annexin V+/PI-) were counted. The data represent 
results from 3 independent experiments. Averages and SD are shown.  
 
3.6  Apoptosis induced by the combination of Smac mimetic and TRAIL treatment is 
independent of intrinsic apoptotic pathway. 
                         It is reported in the literature that caspase 8/10 can cleave BID via TRAIL 
binding to death receptor and formation of the DISC complex 
114
. The cleaved form of BID, 
tBID, can activate the intrinsic pathway by penetrating the mitochondria membrane and 
release a group of pro-apoptotic proteins from mitochondria, such as Cytochrome-c and 
Smac. Pro-apoptotic proteins other than Smac may also contribute to the TRAIL induced 
apoptosis. To determine whether the intrinsic apoptotic pathway also plays a role in the 
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apoptosis induced by TRAIL in KRAS mutant cells, Bcl2 and Bcl-xL constructs were 
transfected into mutant KRAS HBE4 cells (Fig. 14A). Overexpression of either Bcl2 or Bcl-xL 
did not prevent the TRAIL-induced apoptosis (Fig. 14B). These results suggest that the 
apoptosis activated by TRAIL and Smac mimetic is independent of mitochondrial apoptotic 
pathway.  
 
  
 
 
Figure 14. Overexpression of Bcl2 or Bcl-xL in KRAS mutant HBE4 cells did not 
rescue the cells from death. A, HBE4 cells were transfected with either vector or 
Bcl2 or Bcl-xL constructs after KRAS infection. B, Induction of apoptosis. HBE4 cells 
with various infection and transfection combinations were either treated with 
TRAIL or not treated. Apoptotic cells (Annexin V+/PI-) were counted. The data 
represent results from 3 independent experiments. Averages and SD are shown.  
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3.7 Induction of carcinogenesis in a mouse model of KRAS driven lung cancer. 
                         Previous results have showed that activation of KRAS specifically sensitizes 
normal lung epithelial cells to the induction of apoptosis by the combination of TRAIL and 
Smac mimetic in vivo.  To further test the effect of TRAIL and Smac mimetic-mediated 
apoptosis for chemoprevention, we first needed to establish a mouse model with KRAS 
activation, which mimics the process of carcinogenesis in humans. For this purpose, I chose 
a mouse model of mutant KRAS (KRAS-G12D)–driven lung adenocarcinoma. KRAS-G12D 
mice carry a conditional allele of oncogenic KRAS-G12D (LSL-KRAS-G12D) and closely 
mimics the tumorigenesis initiated in humans through somatic KRAS mutation 
150
. LSL-
KRAS-G12D contains a floxed transcriptional stop element, and infecting the lungs of these 
mice with AdenoCre virus, a recombinant adenovirus expressing the Cre recombinase, 
resulted in the expression of mutant KRAS and the development of epithelial hyperplasia of 
the bronchioles, adenomas, and eventually pulmonary adenocarcinoma 
150
. Using the dose 
of AdenoCre virus mentioned before, I sacrificed the mice at 3 wks and 6 wks post-infection 
(Fig. 15A). Then their lungs were inflated with formalin and fixed in formalin overnight. 
Lung sections were analyzed by hematoxylin and eosin (H&E) staining. The histology results 
show the different stages of carcinogenesis in lung tissue (Fig. 15B). At 3 wks after virus 
infection, there are only a few hyperplasias while the uninfected lung is free of hyperplasia 
as the red arrows indicated.  At 6 wks after virus infection, the number of hyperplasias 
continues to increase and there are some areas containing adenoma-like hyperplasia as the 
yellow arrows indicated.  
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Figure 15. A KRAS lung tumor mice model was established to test the effect of 
TRAIL and Smac mimetic. A, The mice were infected with AdCre-CaPi 
coprecipitates (5 - 10
8
 pfu) intranasally in two 62.5-mL instillations. Six weeks after 
infection, the mice were treated either by 3 time continuous treatments or by 
intermittent treatment, 3 continuous injections a cycle, 3 weeks a cycle, totally 3 
cycles. B, the mice were sacrificed before the infection or 3wks or 6 wks after the 
infection. The lung sections were analyzed by hematoxylin and eosin (H&E) 
staining.  
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3.8 Short-term continuous TRAIL and Smac mimetic treatment inhibits lung tumor growth 
in KRAS transgenic mice. 
                                As TRAIL plus Smac mimetic induces apoptosis in oncogenic KRAS–
expressing cells in vitro, this combination has the potential for chemoprevention through 
short term and intermittent therapy. I tested this potential in vivo beginning 6wks after the 
induction of lung carcinogenesis. The mice received 3 consecutive injections of TRAIL plus 
Smac mimetics within 1 week. Then the mice were sacrificed 1 day following the treatment, 
and the lungs were examined for evidence of tumors by H&E staining. I used cleaved 
caspase-3 immunohistochemistry to evaluate induction of apoptosis. TRAIL plus Smac 
mimetic induced a significant level of apoptosis in lung tumor cells (Fig. 16A). There was no 
evidence of apoptosis in normal lung sections (Fig. 16A). Treated mice had a significantly 
decreased number of lung lesions (hyperplasias and adenomas; versus control mice; Fig. 
16B). The most dramatic decrease was a 97% reduction in advanced lung lesions 
(adenomas; Fig. 16B). Therefore, short-term treatment with TRAIL and Smac mimetic 
inhibited in vivo lung tumor growth. 
 
3.9 Intermittent TRAIL and Smac mimetic treatments strongly inhibit lung tumor growth 
in KRAS transgenic mice. 
                               To test the effect of intermittent TRAIL and Smac mimetics treatment, I 
treated the mice with 3 cycles of the 3-perweek consecutive treatments within 2 months. 
The mice were sacrificed 3 days after the last treatments, and the lungs were examined for 
evidence of tumors by H&E staining. At the time of analysis, most lesions in control mice 
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were adenomas, whereas most lesions in treated mice were hyperplasias (Fig. 16C). A 
minor, but statistically significant, reduction was observed in the total number of lung 
lesions in the treatment group (versus controls; Fig. 16D). More important, the number of 
advanced lesions (adenomas) was greatly reduced in the treatment group (versus controls; 
Fig. 16D). The lower number of total lung lesions in Figure 16D compared to that in Figure 
16B is likely due to the presence of some adenomas, which were more numerous in Figure 
16D, comprising multiple hyperplastic lesions. These results support the ability of TRAIL 
plus Smac mimetic to induce apoptosis in mutant KRAS cells in vivo and support the 
potential of this combination for therapy-like chemoprevention of human lung cancer.  
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Figure 16. Effect of TRAIL and Smac on KRAS-induced lung tumors in mice. A, 
TRAIL and Smac mimetic induce apoptosis in lung tumors of LSL-KRASG12D mice. 
LSL-KRAS-G12D mice were infected with AdenoCre and treated 6 weeks later with 
PBS (control; n ¼ 6) or received 3 consecutive treatments with TRAIL (3 mg/kg) 
plus Smac mimetics (3 mg/kg; n ¼ 6) within 1 week. Mice without infection were 
used as normal controls. Three days after the last treatment, the lung sections 
were stained with an anti–cleaved caspase 3 antibody. Representative 
photomicrographs are shown. Caspase 3 staining was detected only in 
TRAIL/Samc-mimetics treated tumor samples. B, TRAIL and Smac mimetics 
treatment inhibits lung tumor growth. Lung sections were stained with H&E and 
lung lesions were counted. The data are derived from counting within serial 
sections in each mouse. Averages and SD are shown. *, P < 0.05; **, P < 0.001. C, 
Intermittent treatment with TRAIL plus Smac mimetics inhibits adenoma 
formation. LSL-KRAS-G12D mice were infected with AdenoCre. Six weeks later, the 
mice ( n = 6 for each treatment group) were subjected to 3 rounds of intermittent 
treatment in 2 months with either PBS (control) or TRAIL (3 mg/kg) plus Smac 
mimetics (1.5 mg/kg). Lung sections were stained with H&E; representative 
photomicrographs are shown. D, Quantification of lung lesions. Serial sections 
were stained with H&E, and lung lesions were counted. The data are derived from 
counting within serial sections in each mouse. Averages and SD are shown. ***, P 
< 0.0001.  
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                          In this chapter, we observed that the combination of TRAIL and Smac 
mimetic specifically induce apoptosis in KRAS activated normal cells. The induction of 
apoptosis did not require the attendance of RAc because KRAS activation modulates the 
expression TRAIL receptors as RAc did. The KRAS activation sensitize the normal epithelial 
cells to TRAIL plus Smac mimetic induced apoptosis by modulating the expression of c-MYC 
and c-FLIP through the MAPK/ERK pathway. And in the process, Smac mimetic overcomes 
the anti-apoptotic activity of XIAP to facilitate TRAIL-induced apoptosis.  
Then I established a mouse model of mutant KRAS (KRAS-G12D)–driven lung 
adenocarcinoma to mimic the process of carcinogenesis in humans. At 6 wks after virus 
infection, the histology analysis showed there were a number of hyperplasias and some 
adenoma-like hyperplasia. Then short-term TRAIL and Smac mimetic treatments strongly 
induced apoptosis specifically in the hyperplasia area while the intermittent TRAIL and 
Smac mimetic treatments dramatically inhibit lung tumor growth in mice.  
Combined in vitro and in vivo results showed that TRAIL and Smac mimetics 
treatment can specifically and efficiently induced apoptosis in KRAS activated normal lung 
epithelial cells which could mimic the premalignant cells.  The long term intermittent 
treatment results strongly suggest that this approach could be applied for SITEP based 
chemoprevention. 
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CHAPTER 4 Use TRAIL and Smac mimetic for lung cancer treatment    
                         
Previous results have shown that for the first time a synthetic lethal 
interaction among TRAIL, Smac, and constitutive activation of RAS in premalignant 
bronchial epithelial cells with great efficiency and specificity. As mutational activation of 
KRAS occurs in 25-30% of NSCLC17, targeting oncogenic RAS activation with the 
combination of TRAIL and Smac mimetic is a potential new approach for the treatment of 
NSCLC. So in this chapter I investigated the mechanism of TRAIL plus Smac mimetics 
induced apoptosis in lung cancer cells for NSCLC treatment. I also tested the efficacy of 
combination treatment in lung cancer using a tumor xenograft model. Because we also 
observed some KRAS mutant lung cancer cell lines are resistant to TRAIL and Smac mimetic 
induced apoptosis. The mechanism of resistance to the combination treatment are 
explored in some respects. 
 
4.1 TRAIL and Smac mimetic induces apoptosis specifically in KRAS mutant lung cancer 
cell line 
                        To determine whether the TRAIL and Smac mimetic combination treatment 
can be used to treat lung cancer, I first tested whether the combination treatment was able 
to kill lung cancer cell lines. I treated different lung cancer cell lines with and without the 
KRAS mutation. The panel of lung cancer cell lines with KRAS mutation includes H460, H358 
and H157. The panel of lung cancer cell lines with wild type KRAS includes H322 and H661. 
The results indicate that the panel of lung cancer cell lines with KRAS mutation is more 
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sensitive to the combination treatment than the panel of lung cancer cell lines with wild 
type KRAS (Figure 17A&B).  
 
  
Figure 17. Effect of TRAIL and Smac mimetic on lung cancer cell lines with or 
without mutant KRAS. A, induction of apoptosis in mutant KRAS cell lines 
including NCI-H460, NCI-H358 and NCI-H157. B, induction of apopotosis in wild 
type KRAS cell lines including NCI-H322 and NCI-H661. Cells were treated with 
TRAIL and Smac mimetics. Apoptotic cells (Annexin V+/PI-) were counted. The 
data represent results from 3 independent experiments. Averages and SD are 
shown. 
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4.2 Expression of mutant KRAS sensitize KRAS wild type lung cancer cell lines to TRAIL 
and Smac mimetic induced apoptosis.  
                        Previous results showed that the panel of lung cancer cell lines with KRAS 
mutation is more sensitive to the combination treatment, which suggest that KRAS 
mutation is relative to the positive response. To further confirm whether KRAS activation 
sensitizes the KRAS wild type lung cancer cells to TRAIL plus Smac mimetic–induced 
apoptosis, I introduced the activating mutant KRAS
G12V 
into the KRAS wild type lung cancer 
cell line NCI-H322 as previously described for the normal cells. Unsurprisingly, constitutive 
expression of mutant KRAS led to activation of downstream signaling pathways, including 
phosphorylation of ERK and AKT in NCI-H322 cells (Fig. 18A). As expected, the MAPK/ERK 
activation regulate the expression of c-Myc, which in turn inhibits the expression c-FLIP 
(Fig.18A). Because previous data also showed that the KRAS activation enhances the DR4/5 
expression while repressing the DcR1/2 expression, which facilitates TRAIL signaling. So we 
also hypothesize that KRAS activation could modulate the death receptors and decoy 
receptors level in NCI-H322 lung cancer cells as in normal lung epithelial cells. But the 
western blotting results is not consist with previous results (Fig. 18A). In NCI-H322 cells, 
only the DR5 expression level was slightly up-regulated but the DR4 level was not. The 
decoy death receptors DcR1/2 were not depressed as in in normal lung epithelial cells.  
Then, to test whether KRAS activation sensitizes NCI-H322 lung cancer cells to 
TRAIL plus Smac mimetics induced apoptosis, NCI-H322 cells infected with vector or 
mutant KRAS retrovirus were treated by Smac mimetic for 30min, then followed by TRAIL 
treatment. After 24 hours post TRAIL treatment, the apoptotic cells were determined with 
annexin V-FITC apoptosis detection kit. Results showed that NCI-H322 cells infected with 
vector virus are resistant to apoptosis induced by TRAIL plus Smac mimetic treatment while 
expression of mutant KRAS sensitized part of the cells to TRAIL plus Smac mimetic induced 
apoptosis (Fig. 18B). These results suggest that activation of KRAS may specifically sensitize 
KRAS wild type lung cancer cell NCI-H322 to TRAIL and Smac mimetic induced apoptosis.  
Comparing to the results in normal lung epithelial cells, the apoptosis was induced in only 
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about 40% NCI-H322 lung cancer cells even the c-MYC and c-FLIP levels were regulated as 
we expected. Considering   the death receptors DR4/5 were not up-regulated as in normal 
lung epithelial cells, it may suggest that death receptors level are one of the key factors to 
decide the cells response to TRAIL plus Smac mimetics induced co-treatment.                                                                                
                        
 Figure 18. Effect of TRAIL and Smac on wild type KRAS lung cancer cell line after 
KRAS activation. A, these cells were infected with either vector (vec) or mutant 
KRAS expressing retrovirus. Activation of KRAS induct phosphorylation of ERK (p-
ERK) and AKT (p-AKT), activation of c-Myc and repression of c-FLIP by KRAS in NCI-
H322 cells. The results also showed effect of KRAS activation on the TRAIL 
receptors DR4, DR5, DcR1, DcR2 and pro-caspase 8. B, KRAS-mediated H322 cells 
were infected with either control or KRAS-expressing retrovirus.  H322 cells were 
infected with either control or KRAS-expressing retrovirus. B, induction of 
apoptosis by TRAIL and Smac mimetics. H322 cells expressing oncogenic KRAS 
were treated with TRAIL (100 ng/mL) or Smac mimetics (100 nmol/L) or both or 
control (PBS) for 24 hours. Apoptotic cells (Annexin V
+
/PI
-
) were counted. The data 
represent results from 3 independent experiments. Averages and SD are shown.  
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4.3 TRAIL and Smac mimetic mediate tumor growth suppression in KRAS activated lung 
cancer xenograft model via induction of apoptosis. 
                   Previous results showed that lung cancer cell lines with KRAS mutation is more 
sensitive to the TRAIL plus Smac mimetic treatment. And activation of KRAS also sensitize 
KRAS wild type lung cancer cell NCI-H322 to TRAIL and Smac mimetic induced apoptosis.  
Those in vitro results showed the efficient anti-tumor effect of TRAIL and Smac 
combination treatment. To further test the anti-tumor effect of TRAIL and Smac mimetic in 
vivo, I utilized a xenograft tumor model. For this experiment, I injected two different lung 
cancer cell lines, NCI-H460 and NCI-H322 into nude mice to generate xenograft tumors. 
NCI-H460 cell line harbors mutant KRAS while NCI-H322 has the wild KRAS. This enables a 
direct comparison of these two types of lung cancer cell lines with the same treatment. 
                    Since there was no previously published data on the dose of TRAIL and Smac 
mimetic for in vivo lung tumor xenograft models, I used the same Smac mimetic dose (3 
mg/kg) but doubled the TRAIL dose (6 mg/kg) compared with the transgenic KRAS mice 
model. In the NCI-H322 xenograft mice, the growth of tumors was very similar in both 
control and treated animals. However, in the mice with NCI-H460 xenograft, the treated 
group exhibited decreased tumor growth compared to the control group (Fig. 19A). At the 
end of treatment (day 24), the NCI-H322 tumor relative volume  increased 8.23 times in 
control group versus 9.09 times in the mice treated with TRAIL plus Smac mimetics, while 
the NCI-H460 relateive tumor volume increased 8.48 times in control group compared with 
only 2.68 times in treated group (Fig. 19B). Despite the small number of animals in this 
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study, the difference between NCI-H460 control group and treated group is statistically 
significant, and the trend is clear. These in vivo results demonstrate that the combination 
of TRAIL and Smac mimetic only demonstrates an anti-tumor effect in the NCI-H460 
xenograft tumor model, but not in the NCI-H322 xenograft tumor model. Although these 
data are consistent with the in vitro results, I still sought to confirm that the anti-tumor 
effect is due to apoptosis induced by the TRAIL and Smac mimetic, and not some other 
mechanism. To determine this, TUNEL staining was performed on the xenograft tumor 
sections and the results confirm that apoptosis was only induced in the NCI-H460 treated 
group, not in either the NCI-H322 treated group or the NCI-H460 control group (Fig. 19C). 
These TUNEL results confirm that the anti-tumor effect was accomplished through 
apoptosis induced by the TRAIL and Smac mimetic combination treatment.  
  
  
53 
 
 
 
Figure 19. The effects of combination treatment in the in vivo xenograft model. 
A, xenograft tumor growth curves in control and TRAIL plus Smac mimetic treated 
mice. B, the normalized tumor growth fold at the end of treatment (day 24) in 
control and TRAIL plus Smac mimetic treated mice. C, the TUNEL staining results 
of tumor sections in control and TRAIL plus Smac mimetic treated mice.   
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4.4 Resistance in KRAS mutant lung cancer cell lines may be related to the death receptor 
expression levels. 
                      Even though TRAIL and Smac mimetic combination treatment exhibited strong 
killing effects in vitro and in vivo, it still did not kill all of the cells in vitro and it did not 
cause complete regression of the xenograft tumor. This indicates that there may be 
additional mechanisms that are inhibiting activation of apoptosis and protecting the cells 
from death. To investigate possible mechanisms, I first screened additional lung cancer cell 
lines with KRAS mutations. Among those cell lines, I found that the following cell lines are 
resistant to TRAIL and Smac mimetic combination treatment to different extents: A549, 
NCI-H2122 with KRAS mutation and NCI-H2199 with HRAS mutation (Fig.20A).  
                        To investigate the mechanism of resistance to Smac mimetic and TRAIL 
induced apoptosis in KRAS mutant lung cancer cell lines, I first determined the role of 
extrinsic and intrinsic apoptosis in response to treatment with TRAIL and Smac mimetic. 
Overexpression of either Bcl2 or Bcl-xL did not prevent the TRAIL plus Smac mimetic-
induced apoptosis in KRAS mutant lung cancer cell lines NCI-460 and NCI-H358 (Fig. 20B&C). 
These results are consistent with what I observed in KRAS activated HBE cells. This data 
combined with reports that Smac alone can induce apoptosis independent of Apaf-1/Cyt C 
134
, I conclude that TRAIL plus Smac mimetic-induced extrinsic apoptosis is sufficient to 
trigger downstream caspase activation and cell death, without the involvement of the 
intrinsic apoptotic pathway. I next evaluated major components of the extrinsic apoptotic 
pathway in those lung cancer cell lines by western blot (Fig. 20D). The results suggest that 
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the resistance may not be due to cFLIP and cMyc level as in the HBE cells. In contrast, DR5 
and pro-caspase 8 levels are the most likely predictors of responses to TRAIL plus Smac 
mimetic induced apoptosis.  
 
Figure 20. The resistance are highly relative to death receptor DR5. A, Induction 
of apoptosis. Mutant KRAS cell lines including A549 and NCI-H2122, and mutant 
NRAS cell lines NCI-1299, were treated with TRAIL and Smac mimetics. Apoptotic 
cells (Annexin V+/PI-) were counted. B, overexpression of Bcl2 and Bcl-xL in NCI-
H460 and NCI-H358 cells. The Bcl2 and Bcl-xL plasmids were transfected into the 
NCI-H460 and NCI-H358 cells. 24 hour after the transfection, cell lysates were 
collected. C, induction of apoptosis.  NCI-H460 and NCI-H358 with Bcl2 or Bcl-xL 
overexpression were either treated with TRAIL plus Smac mimetics or not treated. 
Apoptotic cells (Annexin V+/PI-) were counted. D, Comparison of the extrinsic 
apoptosis pathway components in different lung cell lines. The levels of death 
receptors DR4, DR5 and DcR1; Pro-caspase 8, cFLIP and cMyc are investigated by 
western blotting. All the data represent results from 3 independent experiments. 
Averages and SD are shown. 
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4.5 Increase in DR5 expression via 5Fu stimulation or over-expression can overcome 
resistance to TRAIL and Smac mimetic induced apoptosis. 
                        Previous results showed that death receptors DR5 and pro-caspase 8 levels 
may determine the cell response to TRAIL and Smac mimetic induced apoptosis. To further 
confirm the role of DR5 in determining the response to TRAIL plus Smac mimetic, I 
transfected the DR5 construct into 2 resistant cell lines, A549 and NCI-H2122 (Fig. 21A). 
The overexpression of DR5 alone induced some apoptosis in NCI-H2122 cells but very little 
in A549 cells. However, it can sensitize both A549 and NCI-H2122 to TRAIL plus Smac 
mimetic induced apoptosis (Fig. 21B). This result confirmed that the low DR5 level in 
resistant cell lines may be a key factor of the resistance to apoptotic induction.  
                         To further study the resistance mechanisms, I also screened the combination 
of TRAIL with a panel of anti-tumor drugs for the ability to induce apoptosis in lung cancer 
cell lines. I found that 5-Fluorouracil (5Fu) is the best candidate to synergize with TRAIL to 
induce apoptosis (Fig. 21C). While studying the mechanism of TRAIL and 5Fu synergy, I 
found that 5Fu also up-regulates DR5 levels (Fig. 21D), but not caspase-8 or cFLIP levels 
(data not shown here). The mechanism for 5FU up-regulation of DR5 remained unclear. 
However, these results still suggest the importance of DR5 in TRAIL induced apoptosis.    
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Figure 21. DR5 up-regulation will sensitize the resistant cell lines to TARIL and 
Smac mimetics induced apoptosis. A, overexpression DR5 in NCI-H2122 and A549 
cell lines. DR5 construct was transfected into NCI-H2122 and A549 cells. Lysated 
were collected 24 hours after the transfecdtion. B, cells tranfected with DR5 or 
control plasmids were treated with TRAIL (100 ng/mL) or Smac mimetic (100 
nmol/L) or both or control (PBS) for 24 hours. Apoptotic cells (Annexin V
+
/PI
-
) 
were counted.  C, cells treated with 5Fu or DMSO were treated with TRAIL (100 
ng/mL) or Smac mimetic (100 nmol/L) or both or control (PBS) for 24 hours. 
Apoptotic cells (Annexin V
+
/PI
-
) were counted. D, the DR5 level in cells treated 
with 5Fu increased. The cells were first treated with 5Fu for 24h, then were 
treated with TRAIL (100 ng/mL) or Smac mimetic (100 nmol/L) or both or control 
(PBS) for another 24 hours. Cell lysates were collected. All the data represent 
results from 3 independent experiments. Averages and SD are shown. 
 
 In this chapter, to explore the anti-cancer effect of the combination treatment, 
I first tested the responses of different lung cancer cell lines to the TRAIL and Smac mimetic 
treatment. Results showed that several KRAS mutant lung cancer cell lines are sensitive to 
TRAIL and Smac mimetic induced apoptosis while the KRAS wild type lung cancer cell lines 
are not. KRAS activation in the KRAS wild type lung cancer cells NCI-H322 can sensitize part 
of cells to TRAIL plus Smac mimetic induced apoptosis. In vivo experiment results showed 
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that TRAIL and Smac mimetic treatments strongly inhibit mutant KRAS xenograft tumor 
growth in mice. All the results suggested that the TRAIL and Smac mimetic combination 
treatment has great anti-cancer effect.  
But, the TRAIL and Smac mimetic combination treatment can not completely 
inhibit the tumor growth in mice. And I also observed that some KRAS or NRAS mutant lung 
cancer cell lines are resistant to TRAIL and Smac mimetic induced apoptosis. To enhance 
the anti-cancer effect of the approach, I explored the possible mechanism of resistance.  
The results suggested that the resistance might be relative to the death receptors level in 
lung cancer cells.  Further study showed that the resistance could be overcome by 5-
Fluorouracil or overexpression of DR5. That confirmed the key role of DR5 in determining 
the lung cancer cells response to TRAIL induced apoptosis. 
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CHAPTER 5 Summaries and Discussion  
                          
5.1 Specific targeting of KRAS mutation based on synthetic lethality. 
                           For the first time, my results demonstrate that a synthetic lethal interaction 
exists between TRAIL, Smac mimetic, and constitutively active KRAS in premalignant 
bronchial epithelial cells and malignant lung cancer cells (Fig. 22). This synergy relied on the 
following mechanisms: KRAS up-regulation of c-MYC and thus repressed c-FLIP expression; 
KRAS up-regulated death receptors and down-regulated decoy receptors; and Smac 
mimetic repression of the apoptotic inhibitory effect of IAPs (particularly XIAP). This 
synthetic lethal interaction made it possible to eliminate KRAS-activated premalignant lung 
cells or mutant KRAS lung cancer cells using TRAIL plus Smac mimetic with great efficacy 
and specificity. Normal cells are not sensitive to the combined treatment because of the 
high level of cFLIP and decoy receptors. This is the rationale for pursuing the treatment or 
chemoprevention of KRAS mutant lung cancer. As mutational activation of KRAS occurs in 
approximately 25-30% of NSCLC and there is currently no good method for treating NSCLC 
with KRAS mutation, targeting oncogenic KRAS activation with the combination of TRAIL 
and Smac mimeti is potentially a new approach for the therapy and chemoprevention of 
NSCLC; this potential is strongly supported by my in vivo animal studies. 
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Figure 22.  Synthetic lethality targets the KRAS mutant cells. This figure shows 
that KRAS activation up-regulates cMYC and thus represses cFLIP; Smac mimetic 
inhibits IAPs; KRAS also modulate the Death receptors and decoyed receptors in 
unknown mechanism. The synergy can sensitize the cells to TRAIL induced 
apoptosis. 
 
5.2 SITEP-based lung cancer chemoprevention via synthetic lethality against KRAS 
mutation. 
                           The concept of synthetic lethality is to generate the cell death only when 
there are both mutations in synthetically lethal gene pairs, while a single mutation of either 
gene is compatible with viability. People have begun using this concept to develop cancer-
specific cytotoxic drugs in recent years. There are three advantages of synthetic lethality 
for cancer chemoprevention and therapy. First, synthetic lethality focuses on inducing 
apoptosis instead of inhibiting some oncogenic pathways, which directly kill the cells in a 
short time without leaving creating survival pressure for the cancer cells. This decreases 
the possibility of selection of more resistant malignant cancer cells. Second, cancer-specific 
mutation makes the associated synthetic lethality interactions very specific and selective. 
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The interactions will not harm the normal cells that lack the cancer-specific mutation while 
killing of cancer cells with the mutation, which means this approach should improve 
toxicity and decrease side effects in patients. Third, while using the synthetic lethality as a 
prevention strategy, it is not necessary to constitutively administer agents. Applying 
treatment periodically would eliminate the premalignant cells and decrease the cancer risk, 
which further decrease the toxicity and the possibility to generate the resistance. These 
advantages lead to the idea of short-term intermittent therapy to eliminate premalignancy 
(SITEP), which periodically reduces premalignant tumor cell numbers with short 
interventions to substantially inhibit or delay cancer development.  
                           Compared to the current chemoprevention strategies, SITEP should reduce 
the potential side effects and cost associated with long-term drug administration. It also 
could be predicted that the intermittent treatment would decrease the possibility of 
generating drug resistance by selectively killing premalignant cells without inducing 
metabolic changes in adjacent cells.  
 
5.3 Obstacles to apply this new strategy into clinical trial for KRAS mutant NSCLC  
                            Even though the in vitro and in vivo results showed a promising trend, there 
are still a number of obstacles in translating this strategy into clinical trials. Both rhTRAIL 
and various Smac mimetics have been tested separately in a series of clinical trials and 
showed very little toxicity in patients 
125, 145
. But that does not guarantee that the 
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combination of TRAIL and Smac mimetic are not toxic to patients. Further experiments are 
required to evaluate the potential toxicity of this combination.                 
                            For the purpose of chemoprevention, not only are powerful killing effects 
required, but also low toxicity and few side effects. This means that lower dosage and 
longer intervals between the two treatment cycles would be best. To keep the balance of 
sufficient killing effect and low toxicity, further research needs to be carried out to test 
different dosage combination of TRAIL and Smac mimetic, including additional intermittent 
periods and modified TRAIL or agonistic antibodies.  
                              In this project, it is found that KRAS activation can modulate the death 
receptors DR4/5 and decoy receptors DcR1/2 level and facilitate the TRAIL triggered 
apoptosis. So the attendance of RAc for generating the synthetic lethality with TRAIL and 
Smac mimetic is not required here. It is also reported by other literature that DR4/5 levels 
are always high in KRAS mutant tumors 
151
. But the mechanism of KRAS activation regulate 
DR4/5 and DcR1/2 remains unclear (Fig. 22). There is study that reported the cMYC can up-
regulate DR5 level 
152
. There is also another study that reported the up-regulation of DR5 
by KRAS activation depended on P53 
153
. But the study in my lab showed that cMYC 
knockdown did not abolish the modulation of DR5 by KRAS. Also the DR5 levels in different 
lung cancer cell lines are not consistent with the condition of KRAS activation or P53 status 
(Fig 20).  Those results suggested there is unknown mechanism behinds it.          
Understanding the regulation mechanism will facilitate application of TRAIL based 
treatment or chemoprevention.  
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Previous results showed that up-regulation of DR5 by direct overexpression 
or indirect stimulus could sensitize the resistant NSCLC cells to TRAIL induced apoptosis. 
Those results suggested that DR5 level or DR5/decoy receptor ratio may be the key factor 
to determine the cell response upon TRAIL treatment. If we can get the profiles of death 
receptors and decoy receptors in the patients, we may predict the patient’s response to 
the TRAIL and Smac mimetic combined treatment. Positively modulating the DR5 level also 
could be set as the criteria when we screen the possible candidates which may have the 
synergetic effects with TRAIL, just like the RAc or 5Fu.   
                             In this project, I introduce the KRAS
G12V
 mutant plasmids into normal lung 
epithelial cells or wild type KRAS lung cancer cell lines. But the KRAS
G12V
 mutation could not 
represent all the KRAS mutations because it is reported that there are codon 12, 13 
mutations in NSCLC and different mutations on the same codon, such as G12V and G12D 
mutations 
29
. It is reported that different mutations may activate different downstream 
signals which means the mutations other than G12V may cause different response of cells 
to the TRAIL plus Smac mimetic combination treatment
162
. So I need to introduce different 
KRAS mutations into cells and test the response. This issue also should be concerned for 
the animal model, which is KRAS-G12D mice.  
Some KRAS mutant lung cancer cell lines showed resistance to synthetic 
lethality, while others did not. Resistance may come from the diverse genetic background 
of different cancer cells, which is caused by genome instability. I have demonstrated that 
the level of death receptors is critical to the response to Smac mimetic. The DR4/5 levels 
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are very low in some cell lines. Also the deficiency of downstream key effectors, such as 
caspase 8, will protect the cells from TRAIL induced apoptosis. Although NCI-H460 cells are 
very sensitive to TRAIL plus Smac mimetic treatment, xenograft tumors of this cell line 
cannot be completely inhibited by this combination. One possible explanation is the limited 
activity due to very short half-life of the rhTRAIL, only 5-10 minutes when injected i.v. 
154
. 
To overcome this, some groups have tried to use large proteins coupled to TRAIL to 
increase its stability. Some progress has been made, but increasing toxicity with this 
approach remains a problem 
155
. Agonistic antibodies to TRAIL-R2 (anti-DR5) have been 
tested, but the outcomes are not encouraging 
125
.  This may be due to the poor accessibility 
of large antibodies to tumor tissue. 
                           Whether for therapy or chemoprevention, we need to first target a specific 
population who are most likely to response to treatment. According to the principle of 
synthetic lethality, KRAS mutation is one of the key factors that predict response to Smac 
mimetic and TRAIL, but KRAS mutations occur in both tobacco users and non-smoking 
patients, which makes selection of a target population more difficult. Among the tobacco 
users there are current or prior smokers. Is the KRAS mutation the only criteria for those 
different populations? Are other mutations necessary or exclusive for sensitizing cells to 
the treatment? Are there any biomarkers or risk factors that can be used to assess the 
potential effects?   These questions remained unanswered so far and they need to be 
addressed in the further development of SITEP.  
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5.4 Strategies to overcome resistance. 
                             With continual treatment, it is difficult to avoid the development of 
resistance due to the selection of malignant and/or drug-resistant cells. The inherent 
genomic instability of cancer allows cells to develop strategies to inhibit cell death, such as 
silencing/attenuating death signaling proteins, or over-expression of anti-apoptotic 
proteins.  
                             To overcome these blockades, we have to activate death signaling 
pathways while inhibiting anti-apoptotic proteins.  In the case of TRAIL plus Smac mimetic, 
one strategy is to search for agents that modulate the extrinsic signaling molecules. As I 
mentioned before, positively modulating the DR5 level could be a standard to screen the 
possible candidates, among which is the 5Fu that could up-regulate DR5 expression. The 
work in my lab also suggested that 5Fu could increase DR5 distribution on the cell 
membrane and some specific region, lipid rafts. The combination of TRAIL and 5Fu showed 
more powerful killing effect than the combination of TRAIL and Smac mimetic in vitro and 
in vivo, especially in those resistant cell lines (data not shown here) 
 Even though my studies demonstrated that TRAIL plus Smac induced 
apoptosis independently of the intrinsic apoptotic pathway, it is likely that activation of the 
intrinsic apoptotic pathway will enhance extrinsic apoptosis. So the addition of agents that 
can penetrate the mitochondria may be another good strategy to overcome resistance. 
There are several Bcl-2/Bcl-xL inhibitors being studied in clinical trials that may serve as 
partners to enhance TRAIL plus Smac mimetic induced apoptosis 
163-165
.  
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5.5 Prospective studies 
                           For the coming next step, I will focus on solving the questions and obstacles 
mentioned in the previous discussion part. First we need to completely understand how 
KRAS modulate the death receptors and decoy death receptors levels, which might be the 
key factor to determine the cell response to TRAIL triggered apoptosis. The work in my lab 
had shown that the modulation of death receptors by KRAS is mainly based on the 
transcription level.  So my lab had cloned different promoter and regulation region of 
death receptors into reporter vector. Then we can test which downstream signals of KRAS 
mainly accounts for regulating the transcription of death receptors. After understanding 
how KRAS modulate the death receptors, we could enhance the modulation and even 
sensitize the resistant cell to TRAIL induced apoptosis. 
                           Previous results showed that the premalignant cells or lesions all response 
well to the TRAIL plus Smac mimetic treatment while there are more resistances in cancer 
cells due to the genome instability.  So it suggests that the current approach has more 
great potential in cancer prevention other than cancer treatment. But, we should pay more 
attention on the concerns of drug selection and drug resistance before applying the current 
approach into clinical trials. In this project, I applied the SITEP treatment on the infected 
mice for about 3 months and it showed the efficient effect. But the treatment period may 
be till not long enough to evaluate the possible accumulating drug resistance. So I plan to 
keep the SITEP treatment for longer time and get the Kaplan-Meier survival curves, which 
may reveal the possible resistance.  
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                           Besides the above unsolved issues, one of the most difficult obstacles in 
cancer treatment might be the genomic instability, which generate the diverse genetic 
background of cancer cells and the resistance to the chemotherapy. So we need a mice 
model to investigate if there will be resistance upon to the TRAIL and Smac mimetic 
combination treatment after losing the genomic stability. Now in my lab, we have crossed 
the conditional P53 knockout mice with LSL-Kras
G12D
 mice. After the mice were infected 
with AdenoCre virus, the wild type P53 is knocked out and the mutant KRAS is activated. 
The histology analysis showed that the adenoma formed faster after the adenovirus 
infection and suggested the tumorigenesis process is accelerated in the mice.  So we plan 
to use this new model to mimic the genomic instability with KRAS activation to test our 
new approach. Previous results have shown that endogenous DR5, cMYC and cFLIP levels 
varied in different lung cancer cell lines with KRAS mutation. That also may be due to the 
genomic instability. To further investigate how genomic instability will affect the cell 
response to the treatment and determine which factors play the key role in sensitizing the 
cells to TRAIL induced apoptosis, we will test more lung cancer cell lines and use the 
database to analysis the relevance of TRAIL sensitivity and genetic information, such as the 
KRAS mutation profiles.  
 The long term and final goal of these studies is to develop a new approach 
for targeting KRAS mutant NSCLC for therapy and chemoprevention. The specificity of this 
treatment relies heavily on the activation KRAS. In patients who have a tumor biopsy, it is 
not difficult to check the genetic backgrounds of the tumor. Indeed, for patients who have 
undergone surgery and are found to have activated KRAS, this strategy may be an effective 
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way to eliminate the remaining cancer cells or metastatic cells, and prevent tumor 
recurrence. However, in the case of chemoprevention, the question is how to select 
patients, or how to identify the high-risk populations? One identifiable group of high risk 
people are heavy smokers. It has been reported in numerous studies that KRAS mutation is 
always associated with heavy smoking and the frequency of KRAS mutation is high in this 
population. So this group might be a good candidate for KRAS targeted chemoprevention. 
Further evaluation should be taken on the heavy smokers for the combined treatment.   
                              For the non-smokers or prior smokers, even though the risk of developing 
cancer is low, there is still the possibility of spontaneous KRAS mutation. Since the KRAS 
mutation is an early event in carcinogenesis and the activation of KRAS will change the 
downstream signaling, it is expected that there would be some small change of proteins in 
the circulation. These proteins could be used as predictive makers for the success of 
synthetic lethality based chemoprevention. The development of microarray techniques and 
proteomics makes it possible to identify good targets from blood samples as biomarkers to 
predict KRAS mutation or the response to treatment.  
                             The synthetic lethality of TRAIL and Smac mimetic is based on the mutation 
but not on the organ site. So this approach could be applied in other cancer types with 
common KRAS mutations, such as pancreatic cancer, of which 90% are reported to harbor 
KRAS mutations. Besides cancers with KRAS mutation, cancers that are associated with the 
activation of growth factor signaling, such as EGFR, which leads to KRAS activation, or 
cancers with activated downstream effectors of KRAS, such as BRAF, could also be 
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potential targets for this approach. In support of this some preliminary data from others in 
our lab has shown that EGFR mutant lung cancer cell lines are sensitive to the combination 
treatment.  
                              In recently years, personalized cancer therapy and cancer prevention have 
been a very hot area of research. Synthetic lethality based therapy or prevention could be 
an important part of the personalized treatment, which provides a strong effect, low 
toxicity and low costs in selected high-risk patients or populations. 
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